Network meta-analysis of finerenone and SGLT2 inhibitors in heart failure with preserved or mildly reduced ejection fraction
New analysis shows finerenone and SGLT2 drugs help lower heart failure hospitalization risks for patients with preserved ejection fraction
This network meta-analysis evaluated finerenone, sodium–glucose cotransporter 2 inhibitors, renin–angiotensin system inhibitors, and angiote…
A large review of over 65,000 patients found that finerenone and SGLT2 inhibitors reduce hospital stays and worsening heart failure compared…
Meta-analysis finds conduction system pacing reduces heart failure hospitalizations in HFmrEF
New pacing method cuts hospital stays for heart failure patients with mildly reduced function
This systematic review and meta-analysis of 1867 patients with heart failure with mildly reduced ejection fraction (HFmrEF) found that condu…
A new pacing method reduced hospital visits for heart failure patients with mildly reduced function compared to standard care.
Structured Exercise Training Improves LVEF and LDL-C in HFmrEF Patients After PCI
Heart function improved more with exercise than medicine alone in stable heart disease patients
This single-center randomized trial of 120 stable CAD patients with HFmrEF (LVEF 40-49%) post-PCI found that adding a 52-week structured exe…
A 52-week program of structured exercise plus standard heart medicines helped heart function recover better than medicines alone in patients…
Higher Lactate Dehydrogenase-to-Albumin Ratio Associated With Increased Readmissions and Mortality in Heart Failure
High Blood Marker Tied to Worse Heart Failure Outcomes
This retrospective cohort study included 1,084 hospitalized patients with heart failure with reduced or mildly reduced ejection fraction.
A new blood marker combo can spot heart failure patients most likely to get worse — helping doctors act sooner.
Research across Heart Failure
Related studies from across the Heart Failure family.
Moderate mitral regurgitation associated with higher risk of primary outcome in HFrEF patients
Trial shows moderate mitral regurgitation impacts heart failure outcomes
This randomized controlled trial of 8232 patients with heart failure and reduced ejection fraction (HFrEF) evaluated the impact of mitral re…
New research identifies that patients with moderate mitral regurgitation may face higher risks in heart failure treatment outcomes.
Prediction models for heart failure in type 2 diabetes show acceptable discrimination but lack prospective testing
New Prediction Models Help Identify Heart Failure Risk in Diabetes
This meta-analysis of 65 studies evaluated prediction models for incident heart failure and heart failure hospitalization in people with typ…
New prediction models show promise in identifying heart failure risks for people living with type 2 diabetes.
Heart transplantation provides feasible treatment with favorable long-term survival for end-stage Chagas heart disease
Heart transplant offers long term survival for Chagas heart disease
This meta-analysis of 305 patients evaluates outcomes in Chagas heart disease transplant recipients. The analysis indicates that heart trans…
Heart transplants provide a viable path to long term survival for patients with advanced Chagas heart disease.
Nursing-led strategies address patient, systemic, and socio-cultural barriers to cardiac rehabilitation participation
Nurses help heart failure patients overcome barriers to cardiac rehab
This systematic review of 17 studies identifies nursing-led interventions as key facilitators for overcoming barriers to cardiac rehabilitat…
Many heart failure patients struggle to join rehab due to fear or travel issues, but nurse-led support can help them stay on track.
Dapagliflozin associated with lower risk of heart failure in frail patients with aortic stenosis
Trial shows dapagliflozin may help frail patients with aortic stenosis
This post hoc analysis examined the impact of dapagliflozin on patients with severe aortic stenosis undergoing transcatheter aortic valve im…
A new analysis suggests the medication dapagliflozin may offer specific benefits for patients with aortic stenosis who are also experiencing…
Cardiac resynchronization therapy increases left ventricular ejection fraction by 9.95% in cancer-related heart failure
Heart therapy shows promise for cancer patients with heart damage
This meta-analysis of 110 patients with cancer therapy-related cardiac dysfunction found that cardiac resynchronization therapy (CRT) increa…
A new look at heart treatments shows that a specific device can improve heart function for cancer survivors with heart damage.
Individualized mechanical circulatory support is necessary as increased hemodynamic support does not uniformly improve survival
Mechanical Support for Cardiogenic Shock Does Not Uniformly Improve Survival
This mini review examines the role of short-term mechanical circulatory support (MCS) in patients with cardiogenic shock, including those wi…
Newer reviews suggest that while mechanical support helps heart function, it does not always lead to better survival rates for patients in c…
Qili Qiangxin plus conventional medicine improves surrogate markers in heart failure after myocardial infarction
Qili Qiangxin May Improve Heart Function After Heart Attack
This meta-analysis of 1391 patients found that Qili Qiangxin combined with conventional Western medicine led to greater reductions in NT-pro…
Adding Qili Qiangxin to standard medicine may improve heart function and quality of life for patients following a heart attack.
RAAS inhibitors modulate inflammatory responses and oxidative stress across multiple chronic conditions
RAAS Inhibitors May Protect Organs Beyond Lowering Blood Pressure
This systematic review synthesizes the roles of ACEI, ARB, DRI, ARNI, and MRA in modulating inflammatory responses and oxidative stress. The…
New research suggests certain blood pressure medications may protect the heart, kidneys, and lungs by reducing inflammation and oxidative st…
An RV-first framework addresses controversies in tricuspid intervention and right ventricular support for cardiogenic shock
New framework aims to improve care for heart failure patients
This narrative review explores the role of transcatheter tricuspid interventions and mechanical circulatory support for patients with advanc…
Doctors are looking for better ways to treat heart failure and cardiogenic shock using a new approach to manage the right side of the heart.
SGLT-2is and GLP-1RAs significantly reduce heart failure related composite endpoints in type 2 diabetes
SGLT2 inhibitors and GLP-1RAs both improve heart failure outcomes
This network meta-analysis of 13,886 patients with type 2 diabetes and heart failure found that both SGLT-2is and GLP-1RAs significantly red…
New data shows both SGLT2 inhibitors and GLP-1RAs effectively reduce heart failure risks for people with type 2 diabetes.
Ventricular Arterial Coupling Surrogates Predict Mortality and Adverse Events in Acute Heart Failure
Ventricular-arterial coupling measures help identify high risk in heart failure
Meta-analysis of 36,989 patients reveals that RV-PA uncoupling predicts mortality while LV-Ao uncoupling identifies risk for in-hospital car…
New data shows that specific heart measurements can help doctors identify which heart failure patients face the highest risk of death or com…
Questions about heart failure with mildly reduced ejection fraction
Are SGLT2 inhibitors effective for treating heart failure with mildly reduced ejection fraction?
Yes, SGLT2 inhibitors are effective for treating heart failure with mildly reduced ejection fraction, reducing heart failure hospitalizations and improving outcomes.
Full answer →Does finerenone help patients with heart failure with mildly reduced ejection fraction?
Yes, finerenone reduces cardiovascular death and worsening heart failure events in patients with heart failure with mildly reduced ejection fraction, based on a network meta-analysis and the FINEARTS-HF trial.
Full answer →Can structured exercise training improve my heart function in HFmrEF after a stent?
Yes, a 52-week structured exercise program significantly improves LVEF (by about 5%) and reduces LDL cholesterol in HFmrEF patients after PCI, beyond standard medications alone.
Full answer →